Truist raised the firm’s price target on Roivant Sciences to $23 from $19 and keeps a Buy rating on the shares. The analyst states that the detailed data presentation from Roivant demonstrates RVT-3101’s robust efficacy across groups in both overall population and biomarker+ population. Truist now awaits additional phase 3 trial details while noting that two Phase 3 trials will be needed for approval, the firm tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ROIV:
- Roivant Sciences price target raised to $11 from $10.50 at BofA
- Roivant Sciences surges 8% after UC treatment shows longer-term effect
- Roivant Rises on Promising Phase 2b Data in Ulcerative Colitis
- Roivant Sciences reports chronic period data for RVT-3101 from TUSCANY-2 study
- Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period